Abstract
6 cases of Behcet's disease are reported. Diagnosis was particularly arduous because the typical triad of symptoms (oral aphthae, genital ulcers, uveitis) was masked by secondary disturbances in other organs and systems. Immunology confirmed the presence in these patients of changes in various in vivo and in vitro tests and particularly interesting was the aspecific cutaneous hypersensitivity seen in 5 cases and enhanced lymphocyte blastic transformation. This was seen spontaneously and following PHA. On the basis of the outcome of the studies carried out and the literature data, the possibility that Behcet's disease may contain immunological changes and changes in the mechanisms that regulate quinine, complement and clotting activation is suggested. Therapeutically, confirmation was obtained of effectiveness, at least temporarily, of corticosteroid treatment and antilymphocyte globulin was experimented for the first time in these patients. This might be used to replace the immune depressant antiblastic substances already successfully employed in patients with Behcet's disease.
| Original language | Italian |
|---|---|
| Pages (from-to) | 3269-3284 |
| Number of pages | 16 |
| Journal | Minerva Medica |
| Volume | 70 |
| Issue number | 48 |
| Publication status | Published - 1979 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
STUDIO CLINICO-IMMUNOLOGICO DI SEI CASI DI MORBO DI BEHCET. / Silingardi, V.; Montemurno, C.; Venezia, L.; Franceschi, C.; Riva, P. C.; Emilia, G.; Masi, M.; Merelli, E.; Torelli, G.; Licastro, F.; Fantini, M. P.; Federico, M.
In: Minerva Medica, Vol. 70, No. 48, 1979, p. 3269-3284.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - STUDIO CLINICO-IMMUNOLOGICO DI SEI CASI DI MORBO DI BEHCET
AU - Silingardi, V.
AU - Montemurno, C.
AU - Venezia, L.
AU - Franceschi, C.
AU - Riva, P. C.
AU - Emilia, G.
AU - Masi, M.
AU - Merelli, E.
AU - Torelli, G.
AU - Licastro, F.
AU - Fantini, M. P.
AU - Federico, M.
PY - 1979
Y1 - 1979
N2 - 6 cases of Behcet's disease are reported. Diagnosis was particularly arduous because the typical triad of symptoms (oral aphthae, genital ulcers, uveitis) was masked by secondary disturbances in other organs and systems. Immunology confirmed the presence in these patients of changes in various in vivo and in vitro tests and particularly interesting was the aspecific cutaneous hypersensitivity seen in 5 cases and enhanced lymphocyte blastic transformation. This was seen spontaneously and following PHA. On the basis of the outcome of the studies carried out and the literature data, the possibility that Behcet's disease may contain immunological changes and changes in the mechanisms that regulate quinine, complement and clotting activation is suggested. Therapeutically, confirmation was obtained of effectiveness, at least temporarily, of corticosteroid treatment and antilymphocyte globulin was experimented for the first time in these patients. This might be used to replace the immune depressant antiblastic substances already successfully employed in patients with Behcet's disease.
AB - 6 cases of Behcet's disease are reported. Diagnosis was particularly arduous because the typical triad of symptoms (oral aphthae, genital ulcers, uveitis) was masked by secondary disturbances in other organs and systems. Immunology confirmed the presence in these patients of changes in various in vivo and in vitro tests and particularly interesting was the aspecific cutaneous hypersensitivity seen in 5 cases and enhanced lymphocyte blastic transformation. This was seen spontaneously and following PHA. On the basis of the outcome of the studies carried out and the literature data, the possibility that Behcet's disease may contain immunological changes and changes in the mechanisms that regulate quinine, complement and clotting activation is suggested. Therapeutically, confirmation was obtained of effectiveness, at least temporarily, of corticosteroid treatment and antilymphocyte globulin was experimented for the first time in these patients. This might be used to replace the immune depressant antiblastic substances already successfully employed in patients with Behcet's disease.
UR - http://www.scopus.com/inward/record.url?scp=0018609964&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018609964&partnerID=8YFLogxK
M3 - Articolo
VL - 70
SP - 3269
EP - 3284
JO - Minerva Medicolegale e Archivio di Antropologia Criminale
JF - Minerva Medicolegale e Archivio di Antropologia Criminale
SN - 0026-4806
IS - 48
ER -